Cargando…
The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation
Risk stratification in heart failure (HF) patients is an important element for management. There are several risk stratification models that can be used to predict the prognosis of patients with HF, such as Aaronson's scale, CVM-HF (CardioVascular Medicine Heart Failure), the Seattle Heart Fail...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283859/ https://www.ncbi.nlm.nih.gov/pubmed/26336418 http://dx.doi.org/10.5114/kitp.2014.43847 |
_version_ | 1782351326732091392 |
---|---|
author | Szyguła-Jurkiewicz, Bożena Zakliczyński, Michał Andrejczuk, Mariusz Mościński, Mateusz Zembala, Marian |
author_facet | Szyguła-Jurkiewicz, Bożena Zakliczyński, Michał Andrejczuk, Mariusz Mościński, Mateusz Zembala, Marian |
author_sort | Szyguła-Jurkiewicz, Bożena |
collection | PubMed |
description | Risk stratification in heart failure (HF) patients is an important element for management. There are several risk stratification models that can be used to predict the prognosis of patients with HF, such as Aaronson's scale, CVM-HF (CardioVascular Medicine Heart Failure), the Seattle Heart Failure Model (SHFM) and the Munich score. These models fail to adequately address the impact of multiorgan dysfunction on prognosis. The classical Model for End-Stage Liver Disease (MELD) score consists of: total bilirubin, INR (international normalized ratio) and creatinine level. There are some modifications of the MELD scale: MELD-XI, which excludes the INR score; the mod-MELD score, in which INR is replaced with albumin levels; and MELD-Na, which consists of the bilirubin and creatinine levels, INR ratio and the sodium level. Therefore, the MELD score systems are markers of multisystem dysfunction (renal, cardiac, hepatic). It is important that they are composed of routinely collected laboratory measures which are easy to use. |
format | Online Article Text |
id | pubmed-4283859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-42838592015-09-02 The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation Szyguła-Jurkiewicz, Bożena Zakliczyński, Michał Andrejczuk, Mariusz Mościński, Mateusz Zembala, Marian Kardiochir Torakochirurgia Pol Heart and Lung Failure, Transplantology Risk stratification in heart failure (HF) patients is an important element for management. There are several risk stratification models that can be used to predict the prognosis of patients with HF, such as Aaronson's scale, CVM-HF (CardioVascular Medicine Heart Failure), the Seattle Heart Failure Model (SHFM) and the Munich score. These models fail to adequately address the impact of multiorgan dysfunction on prognosis. The classical Model for End-Stage Liver Disease (MELD) score consists of: total bilirubin, INR (international normalized ratio) and creatinine level. There are some modifications of the MELD scale: MELD-XI, which excludes the INR score; the mod-MELD score, in which INR is replaced with albumin levels; and MELD-Na, which consists of the bilirubin and creatinine levels, INR ratio and the sodium level. Therefore, the MELD score systems are markers of multisystem dysfunction (renal, cardiac, hepatic). It is important that they are composed of routinely collected laboratory measures which are easy to use. Termedia Publishing House 2014-06-29 2014-06 /pmc/articles/PMC4283859/ /pubmed/26336418 http://dx.doi.org/10.5114/kitp.2014.43847 Text en Copyright © 2014 http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Heart and Lung Failure, Transplantology Szyguła-Jurkiewicz, Bożena Zakliczyński, Michał Andrejczuk, Mariusz Mościński, Mateusz Zembala, Marian The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation |
title | The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation |
title_full | The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation |
title_fullStr | The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation |
title_full_unstemmed | The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation |
title_short | The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation |
title_sort | model for end-stage liver disease (meld) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation |
topic | Heart and Lung Failure, Transplantology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283859/ https://www.ncbi.nlm.nih.gov/pubmed/26336418 http://dx.doi.org/10.5114/kitp.2014.43847 |
work_keys_str_mv | AT szygułajurkiewiczbozena themodelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation AT zakliczynskimichał themodelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation AT andrejczukmariusz themodelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation AT moscinskimateusz themodelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation AT zembalamarian themodelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation AT szygułajurkiewiczbozena modelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation AT zakliczynskimichał modelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation AT andrejczukmariusz modelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation AT moscinskimateusz modelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation AT zembalamarian modelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation |